Core Viewpoint - MIRXES-B has entered into a memorandum of understanding with Apollo Health and Lifestyle Limited to seek strategic collaboration for the development and commercialization of advanced cancer early detection solutions in India and neighboring countries [1][2] Group 1: Strategic Collaboration - The collaboration aims to establish a joint venture in India with a minimum equity value of $50 million, leveraging the intellectual property, clinical pipeline, research, clinical trial infrastructure, and commercial channels from both companies [1] - Apollo is recognized as a leading healthcare provider in Asia, particularly in preventive oncology and disease management, and is committed to becoming a core player in early disease detection and prevention globally [1] Group 2: Technological Integration - The partnership will combine Mirxes' breakthrough miRNA and multi-omics technologies, core products (GASTROClear and LUNGClear), and its mature clinical pipeline with Apollo's extensive clinical expertise and nationwide hospital network [2] - The goal is to scale the commercialization and market adoption of these solutions, thereby expanding the coverage of early disease screening in the region [2] Group 3: Long-term Strategic Goals - The board views the proposed strategic collaboration as a significant synergistic opportunity that aligns with the long-term strategic goals of the company [2] - The collaboration is expected to address existing gaps in the Indian healthcare system, particularly in early detection and disease screening, and provide a platform for future business expansion in India [2]

Group 1 - MIRXES-B has signed a memorandum of understanding with Apollo Health and Lifestyle Limited to seek strategic cooperation for the development and commercialization of advanced cancer early detection solutions in India and neighboring countries [1] - The anticipated joint venture in India will have a minimum equity value of $50 million, based on the intellectual property, clinical pipeline, research and clinical trial facilities, and commercial channels contributed by both companies [1] - Apollo is recognized as a leading healthcare provider in Asia and aims to enhance its global leadership position in preventive oncology and disease management [1] Group 2 - The collaboration will combine Mirxes' breakthrough miRNA and multi-omics technologies, core products (GASTROClear and LUNGClear), and its mature clinical pipeline with Apollo's extensive clinical expertise and nationwide hospital network [2] - The goal of the partnership is to scale the commercialization and market adoption of these solutions, thereby expanding the coverage of early disease screening in the region [2] - The board believes that this strategic cooperation with Apollo represents a significant synergistic opportunity that aligns with the long-term strategic goals of the company [2]